Development of a safe vaccine to halt the HIV-1 epidemic is an urgent global public health priority. Our Seattle vaccine unit and community have devoted more than 17 years to clinical HIV vaccine development. Our accomplishments include long-standing leadership with the HVTN, an outstanding track record in volunteer enrollment and retention in phase l-lll vaccine trials, and extensive mentorship to new vaccine investigators. In this application, we renew our overall goal to accelerate HIV vaccine development by joining the HIV Vaccine Trials Network (HVTN) as a single comprehensive clinical vaccine trials unit. We propose four specific aims to accomplish our goals:
In Aim 1, we will provide the administrative infrastructure to conduct high quality clinical HIV vaccine research and evaluation.
In Aim 2, we will contribute scientific leadership and clinical research expertise to advance HIV vaccine development through the HVTN.
In Aim 3, we will partner with the Seattle community to enhance communication, education, outreach and recruitment for the successful implementation of HIV vaccine clinical research.
In Aim 4, we will execute phase l-lll HIV vaccine clinical trials in accordance with Good Clinical Practice. We recognize that many obstacles remain in developing a successful HIV-1 vaccine, and the Seattle HVTU will continue its commitment to seek a long-term solution to the HIV-1 epidemic. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069481-06
Application #
8207294
Study Section
Special Emphasis Panel (ZAI1-MPM-A (M2))
Program Officer
Roth, Lynnea L
Project Start
2007-02-01
Project End
2013-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
6
Fiscal Year
2012
Total Cost
$592,662
Indirect Cost
$56,183
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Janes, Holly E; Cohen, Kristen W; Frahm, Nicole et al. (2017) Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 215:1376-1385
Nixon, Daniel E; Bosch, Ronald J; Chan, Ellen S et al. (2017) Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A52 J Clin Lipidol 11:61-69
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med 167:384-393
Gandhi, Rajesh T; McMahon, Deborah K; Bosch, Ronald J et al. (2017) Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog 13:e1006285
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Coban, Hamza; Robertson, Kevin; Smurzynski, Marlene et al. (2017) Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. AIDS 31:1565-1571
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis 215:238-246
Obermeit, Lisa C; Beltran, Jessica; Casaletto, Kaitlin B et al. (2017) Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining ""symptomatic"" versus ""asymptomatic"" HAND. J Neurovirol 23:67-78
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Parker, Robert A; Rabideau, Dustin J; Sax, Paul E et al. (2017) Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. Clin Infect Dis 64:1612-1614

Showing the most recent 10 out of 52 publications